Continuous human malignant hematopoietic (MH) cell lines
Introduction

Continuous cell lines from all hematopoietic cell lineages
The first human continuous hematopoietic cell line was established in 1963 from a 12-year-old African boy with Burkitt's lymphoma (a historical perspective is given in Ref. 1) . Since then several hundred cell lines have been derived from patients with various types of leukemia, lymphoma, or myeloma ( Figure 1 ). Henceforth, we summarize these cell lines under the term 'malignant hematopoietic (MH) cell lines', referring only to human cell lines. Except for the still incompletely explored dendritic cell lineage(s), cell lines are available from all hematopoietic cell lineages; furthermore, these cell lines are arrested in their differentiation at various stages of cell maturation within the distinct cell lineages. 
Figure 1
Total numbers of published cell lines according to different cell line types from 1965 to 1998 (literature summary). The types of cell lines are explained in Table 2 . In this graph are not included: Burkitt lymphoma cell lines, HTLV-I + ATL cell lines and EBV + BLCLs. Shown are only the numbers for well-characterized cell lines. A considerable number of cell lines have been reported that are only incompletely described: B cell precursor, 27; B cell, 43; plasma cell, 38; immature T cell, 6; NK cell, 2; ALCL, 5; myelocytic, 18; monocytic, 4; erythroid-megakaryocytic, 1. A third cohort of cell lines is not characterized at all; the number of these uncharacterized cell lines is not known. ALCL, anaplastic large cell lymphoma; ATL, adult T cell leukemia; B-LCL, B lymphoblastoid cell line; EBV, Epstein-Barr virus; HTLV, human T cell leukemia virus; NK, natural killer.
Reference cell line collections
The development of several public cell line banks with the ensuing availability of large panels of human MH cell lines has tremendously enhanced research in this area. A primary function of cell line banks is to provide authenticated, clean and well-characterized cell material. 2, 3 The most extensive non-profit collection of hematopoietic cell lines has been established at the DSMZ. Other major cell line banks also hold a limited number of the most often used and best-known hematopoietic cell lines: ATCC, JCRB/HSRRB, RIKEN (see Appendix 1 for details). Expansion, authentication, and distribution of cell lines are very costly processes requiring considerable support from the government and other sources. For this reason, evidence of utility and demand for each particular cell line should be considered before it can be accessioned. 2 
New malignant hematopoietic cell lines
There is a steady increase in the number of new MH cell lines published each year (representative example in Figure 2) . However, many cell lines appear in the literature which are Increase in the number of newly published myeloid leukemia cell lines from 1975-1998 (literature summary). The category 'myeloid leukemia cell lines' is presented here as an example for the steady increase in the number of leukemia cell lines established; similar increases were recorded for other categories of MH cell lines. Shown are only the number of well-characterized cell lines published during that time period. The first myeloid cell line published in 1975 was K-562 (reviewed in Ref. 1). The category 'myeloid leukemia cell lines' covers myelocytic, monocytic, and erythrocytic-megakaryocytic cell lines (see also Table 2 ). Note the step-wise increase in the 1980s and again in the 1990s.
insufficiently or not at all characterized. Therefore, we have developed general guidelines for the characterization of new MH cell lines. This paper amplifies a previous publication, 4 and gives special attention to specific recommendations and requirements for an adequate description and publication of new cell lines.
Cardinal features of malignant hematopoietic cell lines
Malignant hematopoietic cell lines
The advent of cell culturing technology and the application of continuous cell lines has provided entirely new approaches for dissecting the hematopoietic compartment. Clearly, MH cell lines have now become indispensable tools in research. 5, 6 They have proven particularly informative in hematological, immunological, molecular biological, cytogenetic, and virological studies, but also in many other fields of biomedicine and biotechnology. One advantage is the unlimited supply of cellular material (Table 1) . Secondly, cell lines may be stored and revived without any detrimental loss of cellular features or cell viability. INK4A and other genes. 9 These genetic changes presumably confer the affected cell either proliferative or survival advantages and are thought to play an important role in tumorgenesis and possibly in the establishment of the cell line.
Intrinsic differences between primary cells and cell line?
In general and under optimal culture conditions, MH cell lines retain very stably the major features of their original cells. It is sometimes taken for granted that some cellular characteristics are acquired during establishment of the cell lines or during extended in vitro culture, thus representing in vitro artefacts. However, there are few if any unequivocal data forthcoming to support such contentions as a general property of cells in culture, eg a direct comparison of the primary cells with the resulting cell line. An alternative view entertains the possibility that this particular abnormality of the malignant in vivo cell may favor its immortalization (or may even represent a prerequisite for immortalization). 9 Finally, suboptimal culture conditions with the ensuing stress on cells and the selection pressure or deliberate experimental manipulations can also lead to phenotypic or genotypic shifts.
Epstein-Barr virus transformed B lymphoblastoid cell lines
A cell line established from a patient with leukemia is not necessarily a 'leukemia cell line'. Early studies from the 1960s established that Epstein-Barr virus (EBV) infection is capable of immortalizing certain B cell subsets in normal human leukocyte cultures but also in samples from patients with malignant hematopoetic cells, hence the designation 'EBV + B lymphoblastoid cell lines (B-LCL)'; this term was adopted to define this type of non-malignant lymphoid cell. 10 The biological activity of EBV is its capacity to growth-transform resting B cells to immortalized lymphoblastoid cells that proliferate indefinitely and harbor the virus in a latent state. Nine EBV genes are expressed as proteins in EBV + B-LCLs which divide continuously in vitro as a result of the expression of these genes. 11 It appears to be 10-to 100-fold easier to establish an EBV + B-LCL from a patient with leukemia than a neoplastic leukemia cell line. 12 The clear distinction between a MH cell line and an EBV + B-LCL is particularly relevant for cell lines established from patients with mature B cell malignancies such as chronic lymphocytic leukemias, hairy cell leukemia, B cell non-Hodgkin's lymphomas, myeloma and other malignancies.
Categorization and classification of malignant hematopoietic cell lines
Categorization of malignant hematopoietic cell lines
There are various possibilities for categorizing human MH cell lines, for instance according to the diagnosis of the patient or according to immunophenotypes, specific cytogenetic alterations, functional characteristics or other features of the cultured cells. The most often used categorization of these cell lines is based on the physiological spectrum of the normal hematopoietic cell lineages: firstly, lymphoid vs myeloid and secondly T cell, B cell, NK cell vs myelocytic, monocytic, megakaryocytic and erythroid (in addition to specific subtypes such as myeloblastic, promyelocytic, eosinophilic, basophilic for the myelocytic cell lineage; B cell precursor, mature B cell, plasma cell for the B cell lineage; and immature and mature T cells) ( Table 2) . It is debatable whether natural killer (NK) cells represent a third lymphoid lineage, 17 or whether they are a branch of the T cell lineage.
Immunophenotypical classification
The most useful technique for assigning a given cell line to one of the major cell lineages is undoubtedly immunophenotyping. The more extensive and complete the immunoprofile, the more precise is the categorization and classification of the cell lineage derivation and status of arrested differentiation along this cell axis. Other techniques may add highly valuable information in cases of uncertainty of cell lineage assignment (see below).
Hodgkin, ALCL and dendritic cell lines
Commonly the assignment of any given hematopoietic cell line to a cell lineage and stage of arrested differentiation, based on its immunological and other phenotypes, does not present any problems. Exceptions to this rule are the Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL)-derived cell lines. Although the lymphoid nature of HodgkinReed-Sternberg cells (the presumed neoplastic cells in HD) appears to be established, 13, 14 and thus HD-derived cell lines may be assigned to lymphoid T or B cell categories, their uniqueness and the fact that such cell lines display very unusual and often asynchronous marker profiles which are not found in normal physiological cells, justifies a separate category for HD cell lines and the equally unique ALCL lines. Continuous human dendritic cell lines have not as yet been described; such presumably unparalleled cell lines with specific profiles will require their own category. Table 5 ) In vitro culture growth kinetics, proliferative characteristics (see Table 5 
Description of new malignant hematopoietic cell lines
We discerned six cardinal requirements for the description and publication of new MH cell lines (Table 3) .
Immortality
A 'continuous cell line' should be grown in permanent uninterrupted culture for at least 6 months, even better for more than a year. This is an important aspect as upon addition of growth factors, primary neoplastic cells or normal cells can be kept in culture for several months before proliferation ceases; these cultures cannot be regarded as 'continuous cell lines'. Furthermore, cells may live but do not grow in vitro (for example B cell lymphoma and myeloma cells may survive with virtually no proliferation for up to 6 months). Thus, is is essential that the time period should be indicated for continuously proliferation cells. Continuous cell lines have been defined as cultures that are apparently capable of an unlimited number of population doublings (immortalization); it should be recognized that an immortalized cell is not necessarily one that is neoplastically or malignantly transformed. 18 As pointed out above, a cell line established from a patient with a tumor is not necessarily a tumor cell line.
Verification of neoplasticity
The neoplastic nature of the cell line should be demonstrated by functional assays or by the detection of clonal cytogenetic abnormalities. Given the overwhelming preponderance of karyotypically abnormal MH cell lines (99%), the detection of an abnormal karyotype in a cell line can be regarded as a necessary (although not sufficient) condition of neoplasticity. Colony formation in methylcellulose or agar (clonogenic assays) is also considered an operational test of neoplasticity. Finally, heterotransplantability of cell lines into immunodeficient mice is often taken as a sign of the malignant nature and furthermore represents an indication of the immortality of the transplanted cells. However, all EBV + B-LCLs will eventually become monoclonal, aneuploid, grow as colonies and form tumors in nude mice. Therefore, the criteria listed for 'neoplasticity' are valid only when an EBV + B-LCL has been excluded.
Authentication
The origin of a new cell line must be proven by authentication, ie it must be shown that the cultured cells are indeed derived from the presumed patient's tumor and are not the result of a cross contamination with an older cell line. We estimate that at least 10% of human MH cell lines are misidentified or cross-contaminated by the original investigator; these are clearly 'false cell lines' (a list of known and proven 'false cell lines' will be published shortly). But this may only be the tip of the iceberg as commonly cell lines are passed from laboratory to laboratory without any identity control. The method of choice for identity control is forensic-type DNA fingerprinting. Microsatellite analysis does not appear to be sufficient as the loci seem to be prone to instability in certain tumor types; immunophenotyping will not suffice either as cell lines of the same category will often have similar if not identical immunoprofiles. The presence of unique cytogenetic marker chromosomes or molecular biological analyses (eg identical clonal gene rearrangement patterns on Southern blots) might also provide unequivocal evidence for the derivation of the cell line from its patient.
Scientific significance and characterization
For the sake of the necessities important for scientific publications, namely novelty and scientific significance, the new cell line should have features not yet detected in previously established cell lines. Thus, the scientific significance of a new cell line depends on its characterization. A thorough characterization of the cells (Table 4) will often detect unique characteristics of cell lines proving their scientific importance.
Availability
The availability of cell lines to other qualified investigators upon request is of the utmost importance. Some journals, including Leukemia and Blood, have adopted the policy that any readily renewable resources, including cell lines published in the journal, shall be made available to all qualified investigators in the field, if not already obtainable from commercial sources. The policy stems from the long-standing scientific principle that authenticity requires reproducibility. While cell lines are proprietary and unique, suitable material transfer agreements can be drawn up between the provider and requester. 19 By providing authenticated and unique biological material, cell line banks play a major role in hematopoietic research; 2,3 thus, authors are encouraged to deposit their cell lines in non-profit reference cell line collections.
Characterization of malignant hematopoietic cell lines
Detailed characterization of cellular features
Since MH cell lines commonly grow as single or clustered cells in suspension or only loosely adherent to the flask, single cell populations can be easily prepared and the cells can thus be characterized and classified. Table 4 lists a variety of parameters useful for the description of the cells and a panel of possible tests applicable to the phenotypic and functional characterization of most cell lines. This necessary multiparameter examination of the cellular phenotype provides important information on the likely cell of origin, the variable stringency of maturation arrest, and any discrepancies in the pattern of normal gene expression. The list is not intended to cover comprehensively all possible informative parameters as with new techniques becoming available and research areas extending to new avenues, other or entirely new features might be of interest to scientists. Thus, only some of the features of the phenotypic profiles of cell lines which are most often studied are highlighted. It is also important to indicate when in the life of a cell line particular data were generated and also whether alterations in the phenotypic features of the cells might occur during prolonged culture.
Core data
Immunophenotypic analysis and cytogenetic karyotyping currently appear to be the most important and informative examinations (Table 4) . While the scope and extent of the analytical characterization of MH cell lines is certainly facultative, a core data set is obligatory and essential for the identification, description and culture of a cell line; these data include the clinical and cell culture description of the cell line (an example for the presumably most often used human leukemia cell line HL-60 is given in Table 5 ). Clearly, the origin of an established cell line must be documented sufficiently. However, it is a cardinal principle that informed consent of the donor of the neoplastic cell line be obtained and that he/she should remain anonymous. It is important to check for mycoplasma contamination and to indicate whether the cells are EBV+.
Sister cell lines and subclones
Subclones of any given cell line and sister cell lines must be distinguished and properly presented (Table 6 ). Serial or longitudinal sister cell lines (eg established at diagnosis and relapse of the same patient) may provide unique opportunities to study the molecular mechanisms involved in disease progression and transformation. 20 Of particular interest also are pairs of cell lines consisting of one cell line with diseased cells and one cell line with normal, albeit EBV-transformed cells from the same patient (which, as a bonus, provide reliable data allowing subsequent authentication).
Synopsis of principal features of a malignant hematopoietic cell line
A summary of the salient characteristics of a new cell line would be of great benefit. Table 7 provides an illustrative example of such a summary table. It might be conceivable to publish new MH cell lines in this form as a short communication or letter, reminiscent of brief genemapping reports as found in the respective literature.
Summary and future directions
MH cell lines constitute invaluable model systems for the laboratory investigation of neoplastic disease. Without doubt, the study of hematological malignancies has been greatly facilitated by the development of cell lines derived from these neoplasms. The altered physiology of cell lines possibly brought about by the neoplastic process in vivo and/or by the adaptation to in vitro culture conditions means that the cell lines cannot be equated with normal hematopoietic cells. Never-theless, since they are the closest in vitro approximation of in vivo neoplastic hematopoietic cells, they provide unique opportunities for studying normal and malignant hematopoiesis. The major advantages are that cell lines are readily manipulated in vitro, can be grown in numbers required for many experiments, can be stored frozen and revived at will.
Progress in understanding the abnormal regulation of hematopoiesis in human leukemias, lymphomas and myelomas would be further enhanced if neoplastic cells, at all stages of the diseases, could be studied easily in cell line models; in other words, if cell lines could be established from any patient. In the past, the establishment of most cell lines appeared to be an unpredictable random process. With newer cell culture techniques, greater experience and the availability of recombinant human growth factors, it has become possible to increase significantly the success rate in attempts to establish cell lines. It is, however, still technically very demanding to produce any cell line at will; currently used cell culture systems are not yet capable of generating cell lines from any given patient or disease. For example, when blood or marrow cells from patients with AML at diagnosis or relapse are placed in semisolid or liquid media in the presence of growth factors, small clusters or colonies of cells with blast-like morphology are observed in the majority of cases; however, it was estimated that only one out of every 10 2 to 10 5 AML blasts proliferates in this system. 24, 25 Thus, it appears that AML cells have limited proliferative capacity suggesting that the leukemic clone is maintained by a small population of cells.
Another conclusion would be that our present in vitro culture conditions do by no means reflect the physiological in vivo microenvironment. Further work is required to mimic more accurately the physiological conditions. It would also be of interest to explore those cellular alterations which appear to confer growth advantages in culture to the minority of explants forming permanent cell lines. Finally, it might be worth examining whether the adaptation of cells to culture has genetic consequences if any.
Efforts should be undertaken so that publications of new cell lines fulfill the requirements listed in Table 3 . The value and scientific significance of a new cell line are obviously correlated with its novelty and the extent of its characterization. It appears that clinical and cell culture data, immunoprofiles and (molecular) cytogenetic characterization are currently of particular importance. The immortality, neoplasticity and monoclonal nature of cell lines and the clonal derivation from the respective tumor biopsy specimen must be demonstrated. It is of the utmost importance that cell lines be distibuted freely to other investigators; furthermore, the awareness of scientists of the benefits of institutionalized cell culture collections should be heightened; otherwise, substantial numbers of unique and potentially important cell lines might be lost. Finally, publication of new cell lines in the format of a synopsis table (Table 7 ) might be of interest to editors and authors alike.
It is anticipated that many more new MH cell lines with unique and significant features will be established in the near future. The expanding library of cell lines will represent extremely important research resources. These powerful research tools will continue to provide valuable information into normal and malignant hematopoiesis.
